Abstract
Purpose
Long-standing hypoglycemia can cause cognitive impairment, and whether recurrent severe hypoglycemia impacts cognitive function in patients with insulinoma has not been studied. This study focused on exploring the cognitive function in patients with insulinoma.
Methods
A prospective study was conducted to assess cognitive function in patients with insulinoma by administering the Montreal Cognitive Assessment (MoCA) questionnaire between January 2016 and July 2017, and patients with cognitive impairment were followed up to undergo the MoCA test 1 year after surgery. The MoCA scores after surgery were compared with the scores before surgery, and the associations between cognitive impairment and relevant factors were further evaluated by multiple linear regression analysis.
Results
Eighteen out of thirty-four patients (53%) with insulinoma were screened positive for cognitive impairment as defined by a MoCA score <26. Performance in certain cognitive domains, including visuospatial and executive functions, delayed memory, attention, language, and abstraction, was significantly worse in patients with cognitive impairment. Multivariate analysis indicated that MoCA scores correlated significantly with tumor grade and years of education. Eight patients with cognitive impairment were lost to follow-up. The remaining ten patients with cognitive impairment showed improvements 1 year postoperatively, and seven patients recovered to normal cognitive function.
Conclusions
Cognitive impairment was found in patients with insulinoma and was reversible in some patients 1 year after surgery. More studies are needed to explore the underlying mechanisms of the existence and reversibility of cognitive impairment in patients with insulinoma.
Similar content being viewed by others
References
F.J. Service, M.M. McMahon, P.C. O’Brien, D.J. Ballard, Functioning insulinoma–incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo. Clin. Proc. 66, 711–719 (1991)
D.C. Metz, R.T. Jensen, Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135, 1469–1492 (2008)
M.H. Kulke, L.B. Anthony, D.L. Bushnell, W.W. de Herder, S.J. Goldsmith, D.S. Klimstra, S.J. Marx, J.L. Pasieka, R.F. Pommier, J.C. Yao, R.T. Jensen, NANETS Treatment Guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39, 735–752 (2010)
W.W. De Herder, B. Niederle, J.Y. Scoazec, S. Pauwels, G. Kloppel, M. Falconi, D.J. Kwekkeboom, K. Oberg, B. Eriksson, B. Wiedenmann, G. Rindi, D. O’Toole, D. Ferone, Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84, 183–188 (2006)
M. Falconi, B. Eriksson, G. Kaltsas, D.K. Bartsch, J. Capdevila, M. Caplin, B. Kos-Kudla, D. Kwekkeboom, G. Rindi, G. Klöppel, N. Reed, R. Kianmanesh, R.T. Jensen; Vienna Consensus Conference participants., ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103, 153–171 (2016)
Y. Ding, S. Wang, J. Liu, Y. Yang, Z. Liu, J. Li, B. Zhang, Y. Chen, M. Ding, Neuropsychiatric profiles of patients with insulinomas. Eur. Neurol. 63, 48–51 (2010)
R.E. Warren, B.M. Frier, Hypoglycaemia and cognitive function. Diabetes Obes. Metab. 7, 493–503 (2005)
B.A. Kirchhoff, H.M. Lugar, S.E. Smith, E.J. Meyer, D.C. Perantie, B.C. Kolody, J.M. Koller, A.M. Arbelaez, J.S. Shimony, T. Hershey, Hypoglycemia-induced changes in regional brain volume and memory function. Diabet. Med. 30, 151–156 (2013)
T. Hershey, D.C. Perantie, S.L. Warren, E.C. Zimmerman, M. Sadler, N.H. White, Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care 28, 2372–2377 (2005)
S.A. Ebadi, P. Darvish, A.J. Fard, B.S. Lima, O.G. Ahangar, Hypoglycemia and cognitive function in diabetic patients. Diabetes Metab. Syndr. 12, 893–896 (2018)
G. Pozzessere, E. Valle, C. D’Alessio, G. Soldati, F. Pierelli, F. Leonetti, M. Foniciello, G. Tamburrano, Effects of spontaneous chronic hypoglycemia on central and peripheral nervous system in insulinoma patients before and after surgery: a neurophysiological follow-up. J. Clin. Endocrinol. Metab. 82, 1447–1451 (1997)
Z.S. Nasreddine, N.A. Phillips, V. Bédirian, S. Charbonneau, V. Whitehead, I. Collin, J.L. Cummings, H. Chertkow, The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005)
V. Hachinski, C. Iadecola, R.C. Petersen, M.M. Breteler, D.L. Nyenhuis, S.E. Black, W.J. Powers, C. DeCarli, J.G. Merino, R.N. Kalaria, H.V. Vinters, D.M. Holtzman, G.A. Rosenberg, A. Wallin, M. Dichgans, J.R. Marler, G.G. Leblanc, National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37, 2220–2241 (2006)
K. Alagiakrishnan, N. Zhao, L. Mereu, P. Senior, A. Senthilselvan, Montreal Cognitive Assessment is superior to standardized Mini-Mental Status Exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed. Res. Int. 2013, 186106 (2013)
S.H. Mohun, M.B. Spitznagel, J. Gunstad, A. Rochette, L.J. Heinberg, Performance on the Montreal Cognitive Assessment (MoCA) in older adults presenting for bariatric surgery. Obes. Surg. 28, 2700–2704 (2018)
C. Frengopoulos, M.W. Payne, R. Viana, S.W. Hunter, MoCA domain score analysis and relation to mobility outcomes in dysvascular lower extremity amputees. Arch. Phys. Med. Rehabil. 99(2), 314–320 (2018)
S. Shaefi, E.R. Marcantonio, A. Mueller, V. Banner-Goodspeed, S.C. Robson, K. Spear, L.E. Otterbein, B.P. O’Gara, D.S. Talmor, B. Subramaniam, Intraoperative oxygen concentration and neurocognition after cardiac surgery: study protocol for a randomized controlled trial. Trials 18, 600 (2017)
H. Dai, Q. Xu, X. Hong, X. Wang, H. Pang, W. Wu, Y. Zhao, Surgery in overweight patients with insulinoma: effects on weight loss. Scand. J. Gastroenterol. 52, 1037–1041 (2017)
F. Tian, X.F. Hong, W.M. Wu, X.L. Han, M.Y. Wang, L. Cong, M.H. Dai, Q. Liao, T.P. Zhang, Y.P. Zhao, Propensity score-matched analysis of robotic versus open surgical enucleation for small pancreatic neuroendocrine tumours. Br. J. Surg. 103, 1358–1364 (2016)
R.V. Lloyd, R.Y. Osamura, G. Klöppel, J. Rosai, in WHO Classification of Tumours of Endocrine Organs, 4th edn. (International Agency for Research on Cancer (IARC), Lyon, 2017).
O.N. Tucker, P.L. Crotty, K.C. Conlon, The management of insulinoma. Br. J. Surg. 293, 264–275 (2006)
R.M. Crum, J.C. Anthony, S.S. Bassett, M.F. Folstein, Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 2386–2391 (1993)
S. Hoops, S. Nazem, A.D. Siderowf, J.E. Duda, S.X. Xie, M.B. Stern, D. Weintraub, Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738–1745 (2009)
C. DeCarli, Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2, 15–21 (2003)
E.C. Puente, J. Silverstein, A.J. Bree, D.R. Musikantow, D.F. Wozniak, S. Maloney, D. Daphna-Iken, S.J. Fisher, Recurrent moderate hypoglycemia ameliorates brain damage and cognitivedysfunction induced by severe hypoglycemia. Diabetes 59, 1055–1062 (2010)
A.J. Sommerfield, I.J. Deary, V. McAulay, B.M. Frier, Short-term, delayed and working memory are impaired during hypoglycemia in individuals with type 1 DM. Diabetes Care 26, 390–396 (2003)
I. Feinkohl, P.P. Aung, M. Keller, C.M. Robertson, J.R. Morling, S. McLachlan, I.J. Deary, B.M. Frier, M.W. Strachan, J.F. Price, Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: The Edinburgh type 2 diabetes study. Diabetes Care 37, 507–515 (2014)
Y.X. Chen, Z.R. Liu, Y. Yu, E.S. Yao, X.H. Liu, L. Liu, Effect of recurrent severe hypoglycemia on cognitive performance in adult patients with diabetes: a meta-analysis. J. Huazhong Univ. Sci. Technol. Med. Sci. 37, 642–648 (2017).
A. Couvelard. Pathological evaluation and classification of digestive neuroendocrine tumours. Neuroendocrine tumours: diagnosis and management. S. Yalcin, K. Öberg (eds) (SpringerVerlag, Berlin–Heidelberg), 2015, 59–76
F. Grillo, M. Albertelli, F. Annunziata, M. Boschetti, A. Caff, S. Pigozzi, D. Ferone, L. Mastracci, Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Endocrine 53, 58–62 (2016)
P. Wolf, Y. Winhofer, S. Smajis, C.H. Anderwald, C. Scheuba, B. Niederle, A. Gessl, A. Luger, M. Krebs, O. Koperek, Clinical presentation in insulinoma predicts histopathological tumour characteristics. Clin. Endocrinol. 83, 67–71 (2015)
C. Iadecola, Hypertension and dementia. Hypertension 64, 3–5 (2014)
Acknowledgements
This work was supported by the National Natural Science Foundation of China (81573009, 81773292, 81603157) and Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-I2M 2017-I2M-1-001).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The study protocol (S-K654) was approved by the Institutional Ethics Committee of PUMCH, Chinese Academy of Medical Sciences.
Informed consent
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
About this article
Cite this article
Dai, H., Chen, H., Hong, X. et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine 65, 524–530 (2019). https://doi.org/10.1007/s12020-019-01994-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01994-x